ClinicalTrials.gg
CompletedNCT02413398DERIVEUpdated Oct 31, 2018Results posted

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

A Phase 3 interventional study of Dapagliflozin 10 mg and Matching Placebo for Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 87 sites in 8 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-10-31.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
42nd of 180
321 · median 82
Started
2015
with 14 others
Phase 3
47 of 180
4 open now
Registered
57th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 42nd largest by enrollment, is one of 15 that started in 2015, is one of 47 in phase 3, and was the 57th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at approximately 100 centres from countries across North America and European regions. It is planned to randomize a total of 302 patients.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male aged ≥18 years and \<75 years.
  • History of T2DM for more than 12 months.
  • Inadequate glycemic control, defined as ≥7.0% and ≤11%
  • Stable anti-diabetic treatment regimen
  • Renal impairment: CKD 3A

Exclusion criteria

Exclusion Criteria:

  • Women of who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.
  • History of diabetic ketoacidosis or hyperosmolar nonketotic coma.
  • Severe uncontrolled hypertension defined as SBP ≥180 mmHg and/or Diastolic Blood Pressure (DBP) ≥110 mmHg
  • Any of the following Cardiovascular (CV)/Vascular Diseases within 3 months of prior to signing the consent at visit 1:

Myocardial infarction, Cardiac surgery or revascularization(CABG/PTCA), Unstable angina, Unstable heart failure (HF), HF (NYHA) Class IV, (TIA) or significant cerebrovascular disease, Unstable or previously undiagnosed arrhythmia.

  • History of any or imaging verifying intercurrent kidney disease (such as glomerular nephritis or sign of renal artery stenosis) other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis.
  • Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency.
  • Ongoing treatment with any SGLT2-inhibitor, GLP-1 analogue, or rapid/short acting insulins at screening.
  • Participation in another clinical study with an Product (IP) during the last 30 days prior to signing the consent at visit 1.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
321 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    10 mg Tablets, Oral, Once daily, 24 weeks

    Drug: Dapagliflozin 10 mg

  • Placebo comparator
    Placebo

    Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks

    Drug: Matching Placebo for Dapagliflozin

Interventions

  • Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy

    Also known as: Farxiga™

  • DrugMatching Placebo for Dapagliflozin

    Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24

    To compare the mean change from baseline in HbA1c between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" (142 dapaglifozin, 134 placebo) represents the number with change from baseline available at Week 24.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24.

    To compare the mean percent change from baseline in total body weight between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.

    Time frame: Baseline, Week 24

  2. Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24.

    To compare the mean change from baseline in FPG between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.

    Time frame: Baseline, Week 24

  3. Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.

    To compare the mean change from baseline in seated systolic blood pressure (SBP) between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.

    Time frame: Baseline, Week 24

07

Results

Posted Oct 31, 2018

Participant flow

Participant flow — Overall Study
MilestoneDapagliflozin 10mg QDPlacebo QD
Started160161
Completed156154
Not completed47
Withdrew: Lost to follow-up24
Withdrew: Withdrawal by subject11
Withdrew: Other eligibility criteria12

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24

To compare the mean change from baseline in HbA1c between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" (142 dapaglifozin, 134 placebo) represents the number with change from baseline available at Week 24.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24
percentDapagliflozinPlacebo
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24-0.37 ± 0.10-0.03 ± 0.10
Statistical analysis
  • Dapagliflozin vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.34 · 95% CI -0.53 to -0.15
SecondaryAdjusted Mean Percent Change From Baseline in Total Body Weight at Week 24.

To compare the mean percent change from baseline in total body weight between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24.
percent changeDapagliflozinPlacebo
Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24.-3.42 ± 0.32-2.02 ± 0.32
Statistical analysis
  • Dapagliflozin vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.43 · 95% CI -2.15 to -0.69
SecondaryAdjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24.

To compare the mean change from baseline in FPG between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.

Time frame:
Baseline, Week 24
Reported as:
Mean · mg/dL
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24.
mg/dLDapagliflozinPlacebo
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24.-21.46 ± 5.20-4.87 ± 5.13
Statistical analysis
  • Dapagliflozin vs Placebo · Mixed Models Analysis · p = 0.001 · Mean difference (final values): -16.59 · 95% CI -26.73 to -6.45
SecondaryAdjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.

To compare the mean change from baseline in seated systolic blood pressure (SBP) between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.

Time frame:
Baseline, Week 24
Reported as:
Mean · mmHg
Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.
mmHgDapagliflozinPlacebo
Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.-4.8 ± 1.5-1.7 ± 1.5
Statistical analysis
  • Dapagliflozin vs Placebo · Mixed Models Analysis · p = <0.050 · Mean difference (final values): -3.1 · 95% CI -6.3 to 0.0

Adverse events

Collected over Non-serious AEs were included up to the last day of double-blind treatment + 4 days. SAEs were recorded from the time of Informed Consent through included up to the last day of double-blind treatment + 30 days (or to the end of the 3-week follow-up period, whichever came first).. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin 10mg QD0/160 (0%)9/160 (5.6%)0/160 (0%)
Placebo0/161 (0%)14/161 (8.7%)0/161 (0%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventDapagliflozin 10mg QDPlacebo
Acute coronary syndromeCardiac disorders1/1600/161
Acute myocardial infarctionCardiac disorders1/1600/161
Myocardial ischaemiaCardiac disorders1/1600/161
Gingival bleedingGastrointestinal disorders1/1600/161
Diabetic gangreneInfections and infestations1/1600/161
Diabetic metabolic decompensationMetabolism and nutrition disorders1/1600/161
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/1600/161
Ischaemic strokeNervous system disorders1/1601/161
SyncopeNervous system disorders1/1600/161
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1601/161

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dapagliflozin 10mg QDPlaceboTotal
Mean65.3 ± 6.2266.2 ± 6.4965.8 ± 6.36
Age, Customized
Age, Customized(Participants)Dapagliflozin 10mg QDPlaceboTotal
< 65 Years6446110
>= 65 Years96115211
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin 10mg QDPlaceboTotal
Female6970139
Male9191182
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapagliflozin 10mg QDPlaceboTotal
American Indian Or Alaska Native202
Asian5813
Black Or African American111223
Other112
White141140281
Body Mass Index
Body Mass Index(kg/m^2)Dapagliflozin 10mg QDPlaceboTotal
Mean32.6 ± 4.731.6 ± 5.032.1 ± 4.9
Estimated Glomular Filtration Rate (eGFR)
Estimated Glomular Filtration Rate (eGFR)(mL/min/1.73 m^2)Dapagliflozin 10mg QDPlaceboTotal
Mean51.8 ± 4.151.6 ± 3.851.7 ± 3.9
Urine Albumin-to-Creatinine Ratio (UACR)
Urine Albumin-to-Creatinine Ratio (UACR)(mg/g)Dapagliflozin 10mg QDPlaceboTotal
Mean226.91 ± 566.67246.52 ± 775.49236.78 ± 678.81
08

Study locations

87 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Burbank, California 91505, United States
  • Research Site
    Chula Vista, California 91910, United States
  • Research Site
    Concord, California 94520, United States
  • Research Site
    Fullerton, California 92835-3404, United States
  • Research Site
    Huntington Beach, California 92648, United States
  • Research Site
    Los Gatos, California 95032, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Salinas, California 93901-4446, United States
  • Research Site
    Miami Springs, Florida 33166, United States
  • Research Site
    Miami, Florida 33015, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Pembroke Pines, Florida 33027, United States
  • Research Site
    Chicago, Illinois 60643, United States
  • Research Site
    Brownsburg, Indiana 46112, United States
  • Research Site
    Louisville, Kentucky 40213, United States
  • Research Site
    Monroe, Louisiana 71203, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Jackson, Michigan 39209, United States
  • Research Site
    Chesterfield, Missouri 63017, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Chapel Hill, North Carolina 27517, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    San Antonio, Texas 78215, United States
  • Research Site
    San Antonio, Texas 78224, United States
  • Research Site
    Manassas, Virginia 20110, United States
  • Research Site
    Blagoevgrad, 2700, Bulgaria
  • Research Site
    Botevgrad, 2140, Bulgaria
  • Research Site
    Kozloduy, 3320, Bulgaria
  • Research Site
    Kyustendil, 2500, Bulgaria
  • Research Site
    Sofia, 1233, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Stara Zagora, 6000, Bulgaria
  • Research Site
    Red Deer, Alberta T4N 6V7, Canada
  • Research Site
    Surrey, British Columbia V3S 2N6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Brampton, Ontario L6S 0S9, Canada
  • Research Site
    Cambridge, Ontario N1R 6V6, Canada
  • Research Site
    Concord, Ontario L4K 4M2, Canada
  • Research Site
    Courtice, Ontario L1E 3C3, Canada
  • Research Site
    Etobicoke, Ontario M9R 4E1, Canada
  • Research Site
    Guelph, Ontario N1H 1B1, Canada
  • Research Site
    London, Ontario N6G 5A9, Canada
  • Research Site
    North York, Ontario M3J 1N2, Canada
  • Research Site
    Oakville, Ontario L6M 4H8, Canada
  • Research Site
    Sudbury, Ontario P3E 6C3, Canada
  • Research Site
    Toronto, Ontario M3M 0B2, Canada
  • Research Site
    Toronto, Ontario M4G 3E8, Canada
  • Research Site
    Saskatoon, Saskatchewan S7H 5M3, Canada
  • Research Site
    Quebec, G1V 4G2, Canada
  • Research Site
    Cheb, 350 02, Czechia
  • Research Site
    Horovice, 268 01, Czechia
  • Research Site
    Krnov, 794 01, Czechia
  • Research Site
    Kutna Hora, 284 30, Czechia
  • Research Site
    Ostrava, 702 00, Czechia
  • Research Site
    Praha - Klanovice, 190 14, Czechia
  • Research Site
    Praha 10, 104 00, Czechia
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Chieti Scalo, 66013, Italy
  • Research Site
    Milano, 20122, Italy
  • Research Site
    Napoli, 80138, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Pisa, 56100, Italy
  • Research Site
    San Giovanni Rotondo, 71013, Italy
  • Research Site
    Bielsko-Biała, 43-300, Poland
  • Research Site
    Bydgoszcz, 85-231, Poland
  • Research Site
    Mrągowo, 11-700, Poland
  • Research Site
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Research Site
    Tczew, 83-110, Poland
  • Research Site
    Wrocław, 50-403, Poland
  • Research Site
    Łódź, 90-132, Poland
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Alicante, 03010, Spain
  • Research Site
    Ferrol, 15405, Spain
  • Research Site
    La Laguna (Tenerife), 38320, Spain
  • Research Site
    Lérida, 25198, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Pozuelo de Alarcon, 28223, Spain
  • Research Site
    Göteborg, 413 45, Sweden
  • Research Site
    Lund, 221 85, Sweden
  • Research Site
    Stockholm, 111 57, Sweden
  • Research Site
    Stockholm, 11324, Sweden
09

References and documents

Publications

  • Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjostrom CD, Sartipy P; DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10. Erratum In: Diabetes Obes Metab. 2019 Jan;21(1):203. doi: 10.1111/dom.13563. PubMed 29888547 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Nov 2017, 28 months.

Results were first posted in Oct 2018, 11 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 28 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2015
First posted
Apr 9, 2015
StartActual
Jun 15, 2015
Primary completionActual
Nov 7, 2017
CompletionActual
Nov 7, 2017
Results first posted
Oct 31, 2018
Last update
Oct 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02413398
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 9, 2015
Start date
Jun 15, 2015
Primary completion
Nov 7, 2017
Completion
Nov 7, 2017
Results posted
Oct 31, 2018
Last update
Oct 31, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion